https://pharmasprings.com/ijcpms/issue/feed 2025-01-17T13:59:18+0530 Editor editorijcpms@pharmasprings.com Open Journal Systems <div> <img style="width: 100%;" src="https://pharmasprings.com/templates/frontend/pages/slideshow/slideshow2.gif" /></div> <p align="justify">International Journal of Clinical Pharmacokinetics and Medical Sciences <em>(IJCPMS)</em> ISSN: 2583-0953 is established in the year 2021 officially sponsored by <em><strong>pharma springs publication</strong></em>. We are pleased to introduce ourselves as the novel imminent, and sovereign online pharmacy &amp; medical information services in India. The foundation aims to serve as a means for updating the scientific knowledge of the international audience in the research field of science so a correlation can be made between these researchers. IJCPMS will be published quarterly per year in March, Jun, September, and December. The journal publishes the work that contributes significantly to further the scientific knowledge in the areas of pharmaceutical, medical &amp; biological sciences. All contributions to the journal are rigorously refereed and are selected based on the quality and originality of the work.</p> https://pharmasprings.com/ijcpms/article/view/700 2025-01-17T13:59:18+0530 Vidavaluru Neelima anudeeppadavala9@gmail.comv P Venkata Anudeep anudeeppadavala9@gmail.comv Venugopalaiah Penabaka anudeeppadavala9@gmail.comv Yadala Prapurna Chandra anudeeppadavala9@gmail.comv

<p>This study tested beclomethasone dipropionate for maximal solubility in aqueous buffers to formulate and evaluate beclomethasone dipropionate ethosomes for transdermal delivery. Compared to traditional liposomes, ethosomal systems can deliver greater concentrations of beclomethasone dipropionate via mice's skin at a regulated release rate. Ethosomal formulations had much greater drug flow values (P G.01). This would suggest that ethanol improves the way drugs pass through the layers of the skin. Of all the generated ethosomal formulations, 22.83 ± 0.56 ?g/cm2/h was the most significant drug flow obtained. The release kinetics mechanism was assessed by fitting the permeation data to the zero-order, first-order, and Higuchi diffusion models. A linear link between the quantity of drug released and the square root of time was discovered, and all permeation profiles followed the Higuchi diffusion model. The primary barrier to drug penetration is bypassed when the medication is transported by ethosomes into the stratum corneum, greatly enhancing skin delivery. However, the amount that this function enhances transdermal flux may depend on several variables, including medication release from vesicles in the stratum corneum.</p>

2025-01-04T00:00:00+0530 Copyright (c) 2025 International Journal of Clinical Pharmacokinetics and Medical Sciences https://pharmasprings.com/ijcpms/article/view/699 2025-01-17T13:40:09+0530 Malapati Lakshmi Sahithi pvenupharma@gmail.com Venugopalaiah Penabaka pvenupharma@gmail.com Yadala Prapurna Chandra pvenupharma@gmail.com

<table width="654"> <tbody> <tr> <td width="483"> <p>This study focuses on the formulation and characterisation of Capecitabine muco-adhesive beads for the treatment of colorectal cancer. The alginate beads were synthesised using the ionotropic external gelation technique. To maximise encapsulation efficiency and control the release of Capecitabine from the alginate beads, precise formulation conditions were implemented. Results from in vitro dissolution studies revealed that formulations incorporating increasing concentrations of sodium alginate with SCMC released the drug more rapidly compared to those formulated with sodium alginate and HPMC. Moreover, beads prepared using a 2% w/v aluminum chloride solution as the gelling agent demonstrated greater rigidity compared to those formed with a 2% w/v calcium chloride solution. This highlights the importance of selecting an appropriate gelling agent to optimise bead structure and functionality. Further research is necessary to develop the most effective formulations of Capecitabine for improved therapeutic outcomes in colorectal cancer treatment.</p> </td> </tr> </tbody> </table>

2025-01-02T00:00:00+0530 Copyright (c) 2025 International Journal of Clinical Pharmacokinetics and Medical Sciences